GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (STU:RB0) » Definitions » Cyclically Adjusted Price-to-FCF

Regenxbio (STU:RB0) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Regenxbio Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenxbio Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Regenxbio's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Cyclically Adjusted Price-to-FCF Chart

Regenxbio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenxbio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenxbio's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Regenxbio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regenxbio's Cyclically Adjusted Price-to-FCF falls into.


;
;

Regenxbio Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Regenxbio's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Regenxbio's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.586/134.9266*134.9266
=0.586

Current CPI (Mar. 2025) = 134.9266.

Regenxbio Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.297 100.684 -0.398
201509 -1.570 100.392 -2.110
201512 -0.160 99.792 -0.216
201603 -0.283 100.470 -0.380
201606 -0.321 101.688 -0.426
201609 -0.473 101.861 -0.627
201612 -0.890 101.863 -1.179
201703 -0.715 102.862 -0.938
201706 -0.326 103.349 -0.426
201709 -0.477 104.136 -0.618
201712 -0.431 104.011 -0.559
201803 1.320 105.290 1.692
201806 1.639 106.317 2.080
201809 -0.578 106.507 -0.732
201812 -0.204 105.998 -0.260
201903 -0.773 107.251 -0.972
201906 -0.707 108.070 -0.883
201909 -0.785 108.329 -0.978
201912 -0.647 108.420 -0.805
202003 -0.981 108.902 -1.215
202006 -0.590 108.767 -0.732
202009 -0.929 109.815 -1.141
202012 0.584 109.897 0.717
202103 -1.508 111.754 -1.821
202106 -1.092 114.631 -1.285
202109 -1.220 115.734 -1.422
202112 5.943 117.630 6.817
202203 -1.414 121.301 -1.573
202206 -1.558 125.017 -1.681
202209 -1.296 125.227 -1.396
202212 -0.978 125.222 -1.054
202303 -1.843 127.348 -1.953
202306 -1.058 128.729 -1.109
202309 -1.084 129.860 -1.126
202312 -0.873 129.419 -0.910
202403 -1.127 131.776 -1.154
202406 -0.844 132.554 -0.859
202409 -0.725 133.029 -0.735
202412 -0.614 133.157 -0.622
202503 0.586 134.927 0.586

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenxbio  (STU:RB0) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Regenxbio Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Regenxbio's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio Business Description

Industry
Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Headlines

No Headlines